Related Experiment Videos
[Method for immunization against tuberculosis using BCG-M vaccine--a preparation with a reduced antigenic load]
Abstract:
Experimental and clinical investigations on the possibility of reducing the antigenic content of the vaccine intended for the immunization of newborn infants have been made. Experiments on guinea pigs and white mice have demonstrated that the reduced dose of the preparation, twice as low by weight (0.025 mg), produces the same level of protection against tuberculosis as the full dose (0.5 mg). A new preparation with reduced antigenic content, vaccine BCG-M, has been developed, the technical specifications for this preparation have been approved, and its serial production has been allowed. Clinical tests have revealed that the use of the new preparation makes it possible to decrease the occurrence of unusual postvaccinal reactions and complications (lymphadenitis, ulceration) 3-fold and at the same time to increase the coverage of infants by primary immunization against tuberculosis by 7-8% annually. Since January 1986 this vaccine has been introduced into medical practice.
Insights
A new, lower-antigen tuberculosis vaccine (BCG-M) provides equivalent protection to the standard vaccine in infants. This reduces adverse reactions and improves immunization coverage, enhancing public health outcomes.
Area of Science:
- Immunology
- Vaccinology
- Pediatric Infectious Diseases
Background:
- Standard BCG vaccine for tuberculosis immunization in newborns carries a risk of post-vaccinal reactions and complications.
- Optimizing vaccine composition is crucial for improving safety and efficacy in infant immunization programs.
Purpose of the Study:
- To investigate the feasibility of reducing the antigenic content of the Bacillus Calmette-Guérin (BCG) vaccine for newborn immunization.
- To develop and evaluate a novel BCG vaccine with reduced antigenic load, termed BCG-M.
Main Methods:
- Animal studies (guinea pigs, white mice) were conducted to compare the protective efficacy of reduced-dose versus full-dose BCG vaccine.
- Clinical trials were performed to assess the safety and effectiveness of the new BCG-M vaccine in infants.
Main Results:
- Experimental studies demonstrated that a reduced dose (0.025 mg) of BCG vaccine provided equivalent protection against tuberculosis compared to the full dose (0.5 mg).
- Clinical investigations showed that BCG-M significantly reduced the incidence of post-vaccinal reactions (lymphadenitis, ulceration) by threefold.
- The introduction of BCG-M led to an annual increase in infant immunization coverage against tuberculosis by 7-8%.
Conclusions:
- The development and implementation of BCG-M, a vaccine with reduced antigenic content, is a safe and effective strategy for infant immunization against tuberculosis.
- BCG-M offers improved safety profile and enhanced immunization coverage, contributing to better control of tuberculosis in pediatric populations.